- Home
- IMTX
IMTX
Immatics N.V.
as 05-17-2024 4:00pm EST
$.
+$.
+.%
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
| Founded: | N/A | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | 1.2B | IPO Year: | N/A |
| Target Price: | $16.00 | AVG Volume (30 days): | 462.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.15 - $13.16 | Next Earning Date: | 05-14-2024 |
| Revenue: | $80,945,652 | Revenue Growth: | -6.58% |
| Revenue Growth (this year): | 11.75% | Revenue Growth (next year): | -2.14% |
Share on Social Networks:
Latest Immatics N.V. News
IMTX Breaking Stock News: Dive into IMTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Immatics Announces First Quarter 2024 Financial Results and Business Update
GlobeNewswire
2 months ago
Immatics Announces Full Year 2023 Financial Results and Corporate Update
Simply Wall St.
2 months ago
With 52% institutional ownership, Immatics N.V. (NASDAQ:IMTX) is a favorite amongst the big guns
Simply Wall St.
4 months ago
Immatics' (NASDAQ:IMTX) investors will be pleased with their notable 35% return over the last year
Business Wire
4 months ago
Pebblebrook Hotel Trust Announces the 12th Annual Pebby Award Nominations
PR Newswire
4 months ago
PacBio to Report Fourth Quarter 2023 Financial Results on February 15, 2024
GlobeNewswire
4 months ago
Taboola to Release Fourth Quarter 2023 Financial Results and Host Earnings Conference Call on February 28, 2024
StockStory
4 months ago